Predication of increased plasma homocysteine level on the prognosis of Chinese patients with first-onset ischemic stroke

Abstract

Epidemiological studies show that increased plasma total homocysteine (tHcy) level was an independent risk factor of cardiovascular diseases. This study was aimed to investigate the relationship between tHcy level and prognosis of first-onset stroke in Chinese people. One hundred ninety six patients with first-onset ischemic stroke and ninety-five patients with first-onset hemorrhagic stroke were enrolled in this study. The patients were divided into two groups in terms of tHcy level (< 18 ?mol/L and ≥ 18 ?mol/L). The plasma tHcy level was detected by a high performance liquid chromatography method with fluorescence detection. All the patients underwent a 5-year follow-up. Survival analysis shows that the probability of death or new vascular events in the ischemic stroke patients with high tHcy level (≥ 18 ?mol/L) was significantly higher than that in the counterparts with lower tHcy level (< 18 ?mol/L) (50.9% and 28.7%, respectively, P = 0.004). The relative risk of death or new vascular events was 2.363 (95% CI, 1.209 to 4.617, P = 0.012) in ischemic stroke patients with high tHcy levels(≥ 18 ?mol/L) compared to those with a lower tHcy level (< 18 ?mol/L). The increased tHcy level was significantly associated with the risk of death or new vascular events (OR, 2.492, 95% CI, 1.148 to 5.407, P = 0.021) in patients with ischemic stroke in the exclusion of the influence of other risk factors such as gender, age, body mass index, plasma cholesterol level, the history of hypertension, diabetes or smoking. However, in the patients with hemorrhagic stroke, there was no significant difference in the probability of death or new vascular events between patients with a high tHcy level and those with a lower tHcy level (33.3% and 28.2%, respectively, P = 0.546). Increased tHcy level was an independent risk factor for a worse outcome in patients with first-onset ischemic stroke, but not in hemorrhagic stroke patients.

References

1. Hankey G J, Eikelboom J W . Homocysteine and vasculardisease. Lancet, 1999, 354(9176): 407–413. doi:10.1016/S0140-6736(98)11058-9
2. Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D . Impaired homocysteine metabolismand atherothrombotic disease. Lab Invest, 2001, 81(5): 645–672
3. Eikelboom J W, Lonn E, Genest J Jr, Hankey G, Yusuf S . Homocyst(e)ine and cardiovascular disease:a critical review of the epidemiologic evidence. Ann Intern Med, 1999, 131(5): 363–375
4. Boushey C J, Beresford S A, Omenn G S, Motulsky A G . A quantitative assessment of plasma homocysteine as a risk factorfor vascular disease: probable benefits of increasing folic acid intakes. JAMA, 1995, 274(13): 1049–1057. doi:10.1001/jama.274.13.1049
5. Wald D S, Law M, Morris J K . Homocysteine and cardiovascular disease: evidence oncausality from a meta-analysis. BMJ, 2002, 325(7374): 1202. doi: 10.1136/bmj.325.7374.1202
6. Klerk M, Verhoef P, Clarke R, Blom H J, Kok F J, Schouten E G . MTHFR 677C→T polymorphism and risk of coronary heart disease:a meta-analysis. JAMA, 2002, 288(16): 2023–2031. doi:10.1001/jama.288.16.2023
7. The Homocysteine StudiesCollaboration. . Homocysteine and risk of ischemic heart disease and stroke:a meta-analysis. JAMA, 2002, 288(16): 2015–2022. doi:10.1001/jama.288.16.2015
8. McCully K S . Vascular pathology of homocysteinemia: implications for the pathogenesisof atherosclerosis. Am J Pathol, 1969, 56(1): 11–128
9. Faraci F M, Lentz S R . Hyperhomocysteinemia, oxidativestress, and cerebral vascular dysfunction. Stroke, 2004, 35(2): 345–347. doi:10.1161/01.STR.0000115161.10646.67
10. Zhang C . Cai Y, Adachi M T, Oshiro S, Aso T, Kaufman R J, Kitajima S . Homocysteine induces programmedcell death in human vascular endothelial cells through activationof the unfolded protein response. J BiolChem, 2001, 276(38): 35867–35874. doi:10.1074/jbc.M100747200
11. Tofler G H, D'Agostino R B, Jacques P F, Bostom A J, Wilson P W, Lipinska I, Mittleman M A, Selhub J . Association between increased homocysteine levels andimpaired fibrinolytic potent: potential mechanism for cardiovascularrisk. Thromb Haemost, 2002, 88(5): 799–804
12. Lonn E, Yusuf S, Arnold M J, Sheridan P, Pogue J, Micks M, McQueen M J, Probstfield J, Fodor G, Held C, Genest J Jr ; Heart OutcomesPrevention Evaluation (HOPE) 2 Investigators. . Homocysteinelowering with folic acid and B vitamin in vascular disease. N Engl J Med, 2006, 354(15): 1567–1577. doi:10.1056/NEJMoa060900
13. Bonaa K H, Njolstad I, Ueland P M, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug J E, Amesen E, Rasmussen K ; NORVIT Trial Investigators. . Homocysteinelowering and cardiovascular events after acute myocardial infarction. N Engl J Med, 2006, 354(15): 1578–1588. doi:10.1056/NEJMoa055227
14. Dusitanond P, Eikelboom J W, Hankey G J, Thom J, Gilmore G, Loh K, Yi Q, Klijn C J, Langton P, van Bockxmeer F M, Baker R, Jamrozik K . Homocysteine-loweringtreatment with folic acid, cobalamin, and pyridoxine does not reduceblood markers of inflammation, endothelial dysfunction, or hypercoagulabilityin patients with previous transient ischemic attack or stroke: a randomizedsubstudy of the VITATOPS trial. Stroke, 2005, 36(1): 144–146. doi:10.1161/01.STR.0000150494.91762.70
15. Van Guelpen B, Hultdin J, Johansson I, Stegmayr B, Hallmans G, Nilsson T K, Weinehall L, Witthoft C, Palmqvist R, Winkvist A . Folate,vitamin B12, and risk of ischemic and hemorrhagic stroke: a prospective,nested case-referent study of plasma concentrations and dietary intake. Stroke, 2005, 36(7): 1426–1431. doi:10.1161/01.STR.0000169934.96354.3a